Medlab CEO presents clinical NanaBis™ update to medical practitioners

Medlab Clinical Ltd’s (ASX:MDC) CEO Dr Sean Hall last night, presented a clinical NanaBis™ update to medical practitioners as part of on-going medical education.

He explained several key aspects of NanaBis™, which is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

A summary was provided of five case studies from five different doctors that were treated with NanaBis™ in Australia under the government-approved Special Access Scheme (SAS).

Notably, the data shows significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction, reduction/replacement of previously prescribed medication (in particular opioids, reduction in pain severity scores, and reduction of symptoms.

READ: Medlab Clinical does deal for global distribution of NanaBis™

Medlab noted that it is extremely pleased with the pooled data collected to date as well as the ongoing regulatory pathway for an approved drug.

NanaBis™ wins head-to-head with approved cannabis drug

Further to previously announced Stage 1 results, NanaBis™ data from that component of the trial was directly compared to published data for an ARTG approved Cannabis Drug.

The head to head comparison demonstrates a similar plasma level of THC and CBD with NanaBis being half the dose.

Similarly, the rate of absorption for NanaBis™ was faster.

Actively pursuing drug approval

Based on trial activity, Medlab is actively pursuing regulatory pathways for  TGA in Australia, FDA in the US and Europe’s EMA

Medlab has a planned framework that should take NanaBis™ to an approved drug.

Proactive caught up with Dr Hall earlier this week for an update

Story by ProactiveInvestors